azd4076
Nucleic acidexperimental
Clinical trial activity
2 trials · 3 clinical orgs · 0 marketing orgs
Phase 1
2
Phase 2
1
Phase 3
0
Phase 4
0
Earliest trial started Nov 1, 2015 (NCT02612662)
Timeline
2010s
- Jan 1, 2015
Earliest Phase 1 Sponsor(trial)
Indications
Mechanism of action
- UnclearINHIBITOR
Unclear inhibitor
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Also known as
- azd4076
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT02826525 | Phase 1/Phase 2 (Phase 2) | Jul 18, 2016 | AstraZeneca, Profil GmbH |
| NCT02612662 | Phase 1 | Nov 1, 2015 | AstraZeneca, Parexel |
Showing 2 of 2 trials
Page 1 / 1
Organizations
Research & Development (3)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| AstraZeneca | For profit | 2 | 2 | 2 | 2015 |
| Parexel | For profit | 1 | 0 | 1 | 2015 |
| Profil GmbH | For profit | 1 | 0 | 1 | 2016 |
3 organizations
Page 1 / 1